{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:41:19Z","timestamp":1794440479461,"version":"4.9.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.seizure.2025.11.019","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:49:14Z","timestamp":1764316154000},"page":"180-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Tocilizumab for super-refractory status epilepticus in children with FIRES: A case series"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-572X","authenticated-orcid":false,"given":"Sumitha","family":"Murugesu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Rithauddin","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0784-2302","authenticated-orcid":false,"given":"Husna Binti","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6412-2400","authenticated-orcid":false,"given":"Jun Xiong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6231-9354","authenticated-orcid":false,"given":"Muhamad Azamin","family":"Anuar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-3498","authenticated-orcid":false,"given":"Teik Beng","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.seizure.2025.11.019_bib0001","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions","volume":"59","author":"Hirsch","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.11.019_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s42494-024-00187-y","article-title":"Potential inflammatory mechanisms of the ketogenic diet against febrile infection-related epilepsy syndrome","volume":"7","author":"Wang","year":"2025","journal-title":"Acta Epileptol"},{"key":"10.1016\/j.seizure.2025.11.019_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5952","article-title":"Anti-inflammatory and immune-mediated therapy for a case of febrile infection-related epilepsy syndrome with rapid recurrence","volume":"10","author":"Kurimoto","year":"2022","journal-title":"Clin Case Rep"},{"issue":"3","key":"10.1016\/j.seizure.2025.11.019_bib0004","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bj.2020.03.009","article-title":"Neurocritical care and targeted immunotherapy for febrile infection-related epilepsy syndrome","volume":"43","author":"Sakuma","year":"2020","journal-title":"Biomed J"},{"issue":"8","key":"10.1016\/j.seizure.2025.11.019_bib0005","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/epi.16275","article-title":"Etiology is the key determinant of neuroinflammation in epilepsy: elevation of cerebrospinal fluid cytokines in febrile infection-related epilepsy syndrome and febrile status epilepticus","volume":"60","author":"Kothur","year":"2019","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2025.11.019_bib0006","doi-asserted-by":"crossref","DOI":"10.5498\/wjp.v15.i1.100297","article-title":"Interleukin-6 in epilepsy and its neuropsychiatric comorbidities: how to bridge the gap","volume":"15","author":"Chen","year":"2025","journal-title":"World J Psychiatry"},{"key":"10.1016\/j.seizure.2025.11.019_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X20979253","article-title":"Interleukin-6 blockade with tocilizumab in anakinra-refractory febrile infection-related epilepsy syndrome (FIRES)","volume":"7","author":"Stredny","year":"2020","journal-title":"Child Neurol Open"},{"issue":"4","key":"10.1016\/j.seizure.2025.11.019_bib0008","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ncn3.12385","article-title":"Extinguishing FIRES using tocilizumab","volume":"8","author":"Chee","year":"2020","journal-title":"Neurol Clin Neurosci"},{"issue":"5","key":"10.1016\/j.seizure.2025.11.019_bib0009","first-page":"1032","article-title":"Treatment of new-onset refractory status epilepticus\/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult","volume":"64","author":"Girardin","year":"2023","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2025.11.019_bib0010","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ana.24806","article-title":"Febrile infection-related epilepsy syndrome treated with anakinra","volume":"80","author":"Kenney-Jung","year":"2016","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2025.11.019_bib0011","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.25374","article-title":"Tocilizumab treatment for new-onset refractory status epilepticus","volume":"84","author":"Jun","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2025.11.019_bib0012","article-title":"Super-refractory status epilepticus treated with high-dose perampanel: case series and literature review","volume":"2019","author":"Newey","year":"2019","journal-title":"Case Rep Crit Care"},{"key":"10.1016\/j.seizure.2025.11.019_bib0013","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2147\/NDT.S177803","article-title":"Febrile infection-related epilepsy syndrome (FIRES): prevalence, impact and management strategies","volume":"15","author":"Serino","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"10.1016\/j.seizure.2025.11.019_bib0014","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/jamapediatrics.2013.5316","article-title":"Relationship between the functional status scale and pediatric performance scales","volume":"168","author":"Pollack","year":"2014","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.seizure.2025.11.019_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1150496","article-title":"A practical approach to in-hospital management of new-onset refractory status epilepticus\/febrile infection related epilepsy syndrome","volume":"14","author":"Sheikh","year":"2023","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2025.11.019_bib0016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ana.26627","article-title":"Cytokines in new-onset refractory status epilepticus predict outcomes","volume":"94","author":"Hanin","year":"2023","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2025.11.019_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200403","article-title":"Identification of distinct biological groups of patients with cryptogenic NORSE via inflammatory profiling","volume":"12","author":"Guillemaud","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.seizure.2025.11.019_bib0018","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.5498\/wjp.v14.i8.1244","article-title":"Exploring the role of interleukin-6 receptor blockade in epilepsy and associated neuropsychiatric conditions through a Mendelian randomization study","volume":"14","author":"Yu","year":"2024","journal-title":"World J Psychiatry"},{"issue":"5","key":"10.1016\/j.seizure.2025.11.019_bib0019","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/epi.17933","article-title":"Second-line immunotherapy in new onset refractory status epilepticus","volume":"65","author":"Hanin","year":"2024","journal-title":"Epilepsia"},{"issue":"9617","key":"10.1016\/j.seizure.2025.11.019_bib0020","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in systemic juvenile idiopathic arthritis","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.seizure.2025.11.019_bib0021","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset Still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.seizure.2025.11.019_bib0022","first-page":"36","article-title":"Tocilizumab use in pediatric autoimmune and neuroinflammatory disorders: a case series","volume":"121","author":"Chiu","year":"2021","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2025.11.019_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.110068","article-title":"The role of ketogenic diets in the treatment of status epilepticus","volume":"160","author":"Schoeler","year":"2024","journal-title":"Epilepsy Behav"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125003218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125003218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:47:49Z","timestamp":1768348069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125003218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"alternative-id":["S1059131125003218"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.11.019","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab for super-refractory status epilepticus in children with FIRES: A case series","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}